<a id='18d47ce3-1d09-4100-80b4-c0e019b0b76e'></a>

Neonatal Parenteral Nutrition (PN)

<a id='3b6e2fd9-54bd-4558-a7b3-7dc2b28c48d8'></a>

NASPGHAN
FOUNDATION

<a id='5cb01519-faf8-4801-8ac3-e25817c5ca45'></a>

CAPTION ERROR

<a id='d3e07714-bdce-4812-9ff0-b4373f95fa20'></a>

# Overview
* Case study
* Indications and Rationale
    * Energy requirements
    * Fluid requirements
    * Dextrose
    * Amino Acids
    * Lipids
* Deficiencies
* Monitoring
* Review of case

<a id='7615a6b2-1e1c-4f1e-900a-836b1466808a'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='0df5f249-ef81-473c-98c8-7c4566018257'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, bold, italicized text "NASPGHAN" on a light blue to white gradient background, with a dark blue curved line beneath it.::>

<a id='89c67b68-94a3-4f91-8da0-aaa885d5e102'></a>

Case

3-week-old boy born at 23-week gestation developed septic shock, renal failure, necrotizing enterocolitis, and bowel perforation. He was treated with peritoneal washouts, drains, antimicrobials, and bowel rest. PN was started on DOL#1, but lipids were intermittently held since birth due to fluid overload and hypertriglyceridemia. He was later diagnosed with intestinal failure-associated liver disease (IFALD) (direct bilirubin > 2 mg/dL) and essential fatty acid deficiency (EFAD) (T:T > 0.2). What is the most appropriate IV lipid emulsion (ILE) for this infant?

A) Hold ILE
B) 100% soybean oil ILE 0.5 g/kg
C) Mixed oil ILE 3 g/kg
D) 100% fish oil ILE 1 g/kg

<a id='b721ca81-7262-4699-a874-2805c3a12669'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='083d1c98-3c6f-4897-a42b-d14010970e39'></a>

CAPTION ERROR

<a id='671613e0-4f8e-41fc-bd19-6ee782d5c2c0'></a>

Indications and Rationale:
Common Indications – Term and Preterm Infants

* Inability to feed due to GI condition or illness
* Failure to meet energy requirements by enteral nutrition
* Anticipated NPO > 3-5 days
* Increased metabolic demands during critical illness

<a id='b43d3827-0de4-4b23-8fae-f80bade1e48b'></a>

NASPGHAN
FOUNDATION

<a id='861eb290-72f4-41da-92b1-a71c762f4da8'></a>

Worthington P, et al. J Parenter Enteral Nutr. 2017;41(3):324-77.
Pediatric Nutrition Support Core Curriculum. Editor: Mark Corkins. ASPEN, 2015.
Robinson DT, et al. J Parenter Enteral Nutr. 2023;47(7):830-58.

<a id='a873e317-1ee8-4524-80e6-1708dfb2fa42'></a>

CAPTION ERROR

<a id='b6c1f16f-09c5-4422-8d99-bca13f6211c9'></a>

Indications and Rationale:
Specific Indications – Preterm Infants

* Higher nutritional requirements for growth and development
* PN should be started after birth as soon as vascular access is obtained
* Gastrointestinal immaturity preventing full enteral feeding

<a id='e1cab489-4ebd-4203-8ad3-0e69bcccbcc3'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='81bd7136-ffff-419b-94de-f729b5c6513a'></a>

Worthington P, et al. J Parenter Enteral Nutr. 2017;41(3):324-77.
Pediatric Nutrition Support Core Curriculum. Editor: Mark Corkins. ASPEN, 2015.
Robinson DT, et al. J Parenter Enteral Nutr. 2023;47(7):830-58.

<a id='3eeaf56b-440a-4fd9-82d1-9e54a3746e23'></a>

CAPTION ERROR

<a id='11d08603-0c31-4dde-a6dc-7a115e2c3343'></a>

# Starter PN
* A stock PN for immediate delivery of basic nutrition until a custom PN is ordered
  * Amino acids, dextrose, and calcium
  * No other electrolytes
  * Additional intravenous fluids with electrolytes may be ordered as needed

<a id='6814d025-0267-40c1-aa8b-40744b46af39'></a>

* Early initiation of PN is critical for premature infants
  * Supports growth and development
  * Prevents catabolism

<a id='b80ae0e9-aec9-42ab-a3af-89a6f1da16eb'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='744add3b-ee98-4982-91e0-e7164a61663b'></a>

Robinson DT, et al. J Parenter Enteral Nutr. 2023;47(7):830-58.

<a id='5762dc5c-72cf-4300-8718-2769ba81e1a0'></a>

CAPTION ERROR

<a id='5d6eb681-209c-4617-8ddc-35612f4efda5'></a>

# Neonatal PN: Energy Requirements

<table><thead><tr><th></th><th></th></tr></thead><tbody><tr><td>Preterm Infant (kcal/kg/day)</td><td>110 - 120</td></tr><tr><td>Term Infant (kcal/kg/day)</td><td>90 - 100</td></tr></tbody></table>

*   Establish daily energy requirements
    *   Consider additional kcal based on clinical condition and postnatal growth
*   Calculate energy needs using current dry weight or birth weight if not yet regained

<a id='49e5e64d-7ee3-40d0-a84d-b96287cd63e4'></a>

NASPGHAN
FOUNDATION

<a id='df1b33e8-f64c-434b-93a3-de53172b622e'></a>

Mirtallo J, et al. J Parenter Enteral Nutr. 2004;28(6):S39-S70.
Joosten K, et al. Clin Nutr. 2018;37(6 Pt B):2309-314.
Pediatric Nutrition Support Core Curriculum. Editor: Mark Corkins. ASPEN, 2015.

<a id='523d8b41-80e7-4410-a50a-85ba678c2e60'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, bold, italicized text "NASPGHAN" on a light blue to white gradient background, with a dark blue curved line beneath it.::>

<a id='6fa4e1d9-93ef-41d4-a318-1a584230bafc'></a>

Neonatal PN: Fluid Requirements

<a id='7ce9d8ef-e0c7-4a48-925c-1bc7dbe0fd96'></a>

<::
| | Day of Life (birth) | Day of Life 1 | Day of Life 2+ |
|---|---|---|---|
| Preterm Infant (mL/kg/day) | 80 - 100 | 120 | 140 |
| Term Infant (mL/kg/day) | 60 - 80 | 100 | 100 - 120 |
: table::>

<a id='eeb619ac-43cf-4c61-b0f3-6ef08468270c'></a>

* Establish total fluid limit or allowance

<a id='8a40aa31-bdf3-4a85-82b2-191fc3160551'></a>

• Determine PN volume
PN = Total Fluid Requirement - (Medications + Flushes + Enteral Nutrition + IVF)

<a id='c8b5e2ad-14b4-4535-8047-23f7feeea206'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='a76d8552-32e7-4466-acc9-b6c021dea14f'></a>

Mirtallo J, et al. J Parenter Enteral Nutr. 2004;28(6):S39-S70.
Pediatric Nutrition Support Core Curriculum. Editor: Mark Corkins. ASPEN, 2015.

<a id='3b8f30f6-f7f6-4a54-a887-73a5b3809fbb'></a>

CAPTION ERROR

<a id='68a9ef86-bbee-4567-b4bb-c44670b166f7'></a>

Neonatal PN: Fluid Requirements – Cont'd
* Adjust fluid requirements for specific clinical situations

<a id='30b2006d-eba0-45af-b92e-cb50c76603b7'></a>

* Increase fluids: consider increasing fluid intake in cases of elevated insensible losses or excessive fluid output
* Diarrhea
* High ostomy outputs
* Polyuria
* Phototherapy for jaundice
* Extensive skin injuries
* Sepsis

<a id='7c23ce68-36d3-47d9-8b2b-5d8dc91ed5e2'></a>

NASPGHAN
FOUNDATION

<a id='349a9fd4-c947-406a-a0c6-5fd5ccbf02f7'></a>

Mirtallo J, et al. J Parenter Enteral Nutr. 2004;28(6):S39–S70.
Pediatric Nutrition Support Core Curriculum. Editor: Mark Corkins. ASPEN, 2015.

<a id='44578a07-f47b-4fc4-9ff2-1c7731000eb3'></a>

CAPTION ERROR

<a id='7a0b9b6a-5699-439b-b493-756e445bbc3c'></a>

Neonatal PN: Fluid Requirements – Cont'd

<a id='22c1e293-ab69-472e-b683-8704a4e947e5'></a>

* Adjust fluid requirements for specific clinical situations

<a id='6b6581d1-2e21-4e1c-929a-1771186acece'></a>

* Reduce fluids: consider reducing fluid intake in scenarios where insensible losses are decreased or there is fluid overload
  * Double walled isolators for premature or critically ill infants
  * Ascites due to liver or renal failure
  * Pulmonary edema
  * Congestive heart failure

<a id='706952da-20c9-471c-a5da-85aef4e5392b'></a>

<::NASPGHAN FOUNDATION: figure::>

<a id='04232797-3b02-4cf7-9f0c-41eeabb7dcf5'></a>

Mirtallo J, et al. J Parenter Enteral Nutr. 2004;28(6):S39-570.
Pediatric Nutrition Support Core Curriculum. Editor: Mark Corkins. ASPEN, 2015.

<a id='f533345e-edcf-4ce9-8f76-bc73d944eeaa'></a>

CAPTION ERROR

<a id='1fb8d559-5eb5-4d12-9d78-b57f9dcd19e9'></a>

Neonatal PN: Dextrose

<a id='a75bed00-2156-4abf-ad66-73f2f7582520'></a>

<::
| | Initiation | Advance By | Goals |
|---|---|---|---|
| Preterm Infant (mg/kg/min) | 5 – 7 | 1 - 2 (or 1-2.5% dextrose) | 10-14 (max 14 – 18) |
| Term Infant (mg/kg/min) | 6 – 9 | 1 - 2 (or 2.5 – 5% dextrose) | 10-14 (max 14 – 18) |
: table::>

<a id='a4f0aebe-6e45-4d3d-830f-3443a1877a10'></a>

* Advance until energy goals met
* Monitor blood glucoses with target blood glucose 70-150 mg/dL
  * Premature infants < 28 weeks are at increased risk of hyperglycemia
  * Insulin should not be used given risk of hypoglycemia
* Maintain minimum Glucose Infusion Rate (GIR) 6 mg/kg/min for brain's energy needs
* Note that GIR > 12.5 mg/kg/min may stimulate lipogenesis from excess glucose

<a id='52b24822-97f5-408f-99f6-7f34ad3905ac'></a>

NASPGHAN
FOUNDATION

<a id='ef173750-defa-44d4-9320-2fc0d45b5a74'></a>

Bresson JL, et al. Pediatr Res. 1989;25(6):645-48.
Ramel S, et al. Neoreviews 2020;21(2):e89-e97.
Pediatric Nutrition Support Core Curriculum. Editor: Mark Corkins. ASPEN, 2015

<a id='8ecb1a0b-94a7-4101-b7f3-a0fc678a1608'></a>

CAPTION ERROR

<a id='23f84cfe-dd7e-4178-93b2-80c2e79fda3f'></a>

Neonatal PN: Amino Acids

<a id='241c697d-e4fb-422a-a620-2292a8009d52'></a>

<table><thead><tr><th></th><th>Initiate at Goal</th></tr></thead><tbody><tr><td>Preterm Infant (g/kg/day)</td><td>3 (max 3.5)</td></tr><tr><td>Term Infant (g/kg/day)</td><td>2.5 – 3</td></tr></tbody></table>

* Start protein at goal
  * Gradual advancement delays reaching target needs, leading to net negative nitrogen balance
  * Limited benefit with protein dose > 3.5 g/kg/day
* Initiating protein > 3 g/kg/day has been linked to sepsis in premature infants

<a id='b172272a-9bfe-447c-9894-c35a25432a2f'></a>

<::NASPGHAN FOUNDATION : figure::>

<a id='41f91356-f694-4de2-9d88-8e3494ed9248'></a>

Robinson DT, et al. J Parenter Enteral Nutr. 2023;47(7):830-58.
Strømmen K, et al. Clin Nutr ESPEN. 2017;18:16-22.

<a id='54722128-eedf-4672-8cdd-d7b8e7d0fcbb'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, italicized text "NASPGHAN" on a blue gradient background, with a sweeping dark blue curved line underneath.::>

<a id='8ca02c68-171a-494a-83ec-29a711598089'></a>

Neonatal PN: Lipids
<::
| | Initiation | Advance By | Goals |
|---|---|---|---|
| Preterm Infant (g/kg/day) | 1 | 0.5 - 1 | 3 |
| Term Infant (g/kg/day) | 1 | 0.5 - 1 | 3 |
: table::>
• Advance gradually to minimize risk of hypertriglyceridemia
• Infuse over 12 - 24 hours depending on formulation and clinical condition
• Insufficient lipids can cause essential fatty acid deficiency (EFAD)
• Excess lipids can cause hypertriglyceridemia

<a id='deb3a1cc-fe83-4758-93a4-8f920982c910'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='4927b209-3c68-4b3e-b244-77480636242a'></a>

Mirtallo J, et al. J Parenter Enteral Nutr. 2004;28(6):S39–S70.

<a id='74b6d2c8-9bc8-4287-85f4-6e91055a7be6'></a>

CAPTION ERROR

<a id='3854bd41-bd5c-453a-bfbe-746c05c4e670'></a>

Types of Intravenous Lipid Emulsions (ILEs)
<::visual content
: chart::>
Four images of intravenous lipid emulsion (ILE) containers are displayed above a table. From left to right, the containers are labeled:
1. "100% Soy oil-based ILE"
2. "Olive, soy oil-based ILE"
3. "Soy, MCT, olive, fish oil-based ILE"
4. "Fish oil-based ILE"

Below these images, a table compares different types of ILEs:

| | 100% SO-ILE | OO, SO-ILE | SO, MCT, OO, FO-ILE | FO-ILE |
|---|---|---|---|---|
| Indication | ILE < 2 weeks EFAD | ILE > 2 weeks EFAD | ILE > 2 weeks EFAD | IFALD EFAD |
| Advantages | ↑↑↑ EFA | Sufficient EFA ↓ Phytosterols | Sufficient EFA ↓ Phytosterols | Sufficient EFA ↓ Triglycerides ↓↓ Phytosterols |
| Disadvantages | ↑ Triglycerides ↑ Phytosterols | EFAD * | EFAD * | ↓ Energy density |
<::>


<a id='20258a77-395e-4974-839d-9a5defe130c5'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='2dfe49ee-88ef-4055-9a12-31f715687435'></a>

Mirtallo J, et al. Nutr Clin Pract. 2020;35:769-82.
Calkins KL, et al. Neoreviews 2020;21(2):e109-e119.

<a id='3c7e2f7b-4c72-433f-847a-a83c0210521b'></a>

* If inadequately dosed

<a id='bffc8979-dc0a-4f9a-82ee-8bbed12ba0a2'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the text "NASPGHAN" in dark blue, bold, italicized letters, set against a blue gradient background that fades from a darker blue at the top to a lighter blue at the bottom. A dark blue curved line sweeps underneath the text, extending from left to right.::>

<a id='fae2f5c3-1b18-4891-a2ee-9c8047bb88ce'></a>

Neonatal PN: Types of ILEs

<a id='99772443-374f-4b94-8365-915bef0476e6'></a>

<::table
| Oil Source | SO-ILE | OO, SO-ILE | SO, MCT, OO, FO-ILE | FO-ILE |
|---|---|---|---|---|
| SO (%) | 100 | 20 | 30 | 0 |
| MCT (%) | 0 | 0 | 30 | 0 |
| OO (%) | 0 | 80 | 25 | 0 |
| FO (%) | 0 | 0 | 15 | 100 |
: table::>

<a id='f33da16e-7e0f-48e6-a82e-957f6862a820'></a>

<::NASPGHAN FOUNDATION: figure::>

<a id='5bb98431-07a6-4ae6-9c5c-bd246efcb3a6'></a>

Chan AP, et al. Clin Perinatol. 2023;50(3):575-89.
Calkins KL, et al. Neoreviews 2020;21(2):e109-e119.

<a id='033f5341-a215-4c90-b946-dd3ddb78c657'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the text "NASPGHAN" in dark blue, set against a light blue rectangular background with a gradient fading to white at the bottom, with a dark blue curved line sweeping underneath the text.::>

<a id='04bf3362-7812-4c22-a98e-2ec25a323cbb'></a>

# Neonatal PN: Types of ILEs
<table id="15-1">
<tr><td id="15-2">Fatty Acid</td><td id="15-3">SO-ILE</td><td id="15-4">OO, SO-ILE</td><td id="15-5">SO, MCT, OO, FO-ILE</td><td id="15-6">FO-ILE</td></tr>
<tr><td id="15-7">Caprylic</td><td id="15-8">0</td><td id="15-9">0</td><td id="15-a">17% ± 0.2%</td><td id="15-b">0</td></tr>
<tr><td id="15-c">Capric</td><td id="15-d">0</td><td id="15-e">0</td><td id="15-f">12% ± 0.2%</td><td id="15-g">0</td></tr>
<tr><td id="15-h">Linoleic, ω-6</td><td id="15-i">44%-62%</td><td id="15-j">18%</td><td id="15-k">14%-25%</td><td id="15-l">1.5%</td></tr>
<tr><td id="15-m">α-Linolenic, ω-3</td><td id="15-n">4%-11%</td><td id="15-o">1.7%</td><td id="15-p">1.5%-3.5%</td><td id="15-q">1.1%</td></tr>
<tr><td id="15-r">ARA, ω-6</td><td id="15-s">0</td><td id="15-t">0.16%</td><td id="15-u">0.5%</td><td id="15-v">0.2%-2%</td></tr>
<tr><td id="15-w">DHA, ω-3</td><td id="15-x">0</td><td id="15-y">0</td><td id="15-z">1%-3.5%</td><td id="15-A">14%-27%</td></tr>
<tr><td id="15-B">EPA, ω-3</td><td id="15-C">0</td><td id="15-D">0</td><td id="15-E">1%-3.5%</td><td id="15-F">13%-26%</td></tr>
<tr><td id="15-G">Oleic acid, ω-9</td><td id="15-H">19%-30%</td><td id="15-I">60%</td><td id="15-J">23%-35%</td><td id="15-K">4%-11%</td></tr>
<tr><td id="15-L">ω-6:ω-3</td><td id="15-M">7:1</td><td id="15-N">9:1</td><td id="15-O">2.5:1</td><td id="15-P">1:8</td></tr>
</table>

<a id='c7ffddc9-db0e-4269-805b-2bae66488593'></a>

NASPGHAN
FOUNDATION

<a id='5558fed1-08db-4158-a987-8de881181e89'></a>

Chan AP, et al. Clin Perinatol. 2023;50(3):575-89.
Calkins KL, et al. Neoreviews 2020;21(2):e109-e119.

<a id='4d1053c3-1c43-4f81-bda9-403d130a40e0'></a>

CAPTION ERROR

<a id='8eef2945-0431-4087-8d97-69bdf3a76ecc'></a>

## Essential Fatty Acid Deficiency

*   Definition
    *   Insufficient supply of essential \u03c9-6 linoleic acid and \u03c9-3 \u03b1-linolenic acid (LA) and
    *   Triene:Tetraene (T:T) or Mead acid:Arachidonic ratio > 0.2

<a id='e5801d19-38de-4b32-907a-f5f2657d1422'></a>

- Risk Factors
  - Prematurity, as maternal transfer of EFAs occurs mainly in the 3rd trimester
  - Low birth weight
  - Prolonged withdrawal, restriction or inappropriate dosage of IV lipids

<a id='a7e2b718-04dc-47fa-90b8-a78dc6618257'></a>

<::NASPGHAN FOUNDATION logo with a blue gradient background::>

<a id='9d034eb4-7b91-4a8f-a3a4-d281d545eab0'></a>

Lagerstedt SA, et al. Mol Genet Metab. 2001;73(1):38-45.

<a id='0c071e7d-5d70-4d10-8fda-3dc9aafee2d0'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the text "NASPGHAN" in dark blue, set against a light blue rectangular background with a gradient fading to white at the bottom, with a dark blue curved line sweeping underneath the text.::>

<a id='d24240af-7496-4149-b6be-0110cf51cc6b'></a>

Metabolism of Polyunsaturated Fatty Acids
<::Metabolism of Polyunsaturated Fatty Acids: flowchart::>
ω-9 Fatty Acids
Oleic Acid (18:1ω-9)
↓
Octadecadienoic Acid (18:2ω-9)
↓
Eicosadienoic Acid (20:2ω-9)
↓
Mead Acid (20:3ω-9)

ω-6 Fatty Acids
Linoleic Acid (18:2ω-6)
↓
Gamma-linolenic Acid (18:3ω-6)
↓
Dihomo-gamma-linolenic Acid (20:3ω-6)
↓
Arachidonic Acid (20:4ω-6)
↓
Docosatetraenoic Acid (22:4ω-6)
↓
Tetracosatetraenoic Acid (24:4ω-6)
↓
Tetracosapentaenoic Acid (24:5ω-6)
↓
Docosapentaenoic Acid (22:5ω-6)

ω-3 Fatty Acids
Alpha-linolenic Acid (18:3ω-3)
↓ Δ-6-desaturase
Octadecatetraenoic Acid (18:4ω-3)
↓ Elongase
Eicosatetraenoic Acid (20:4ω-3)
↓ Δ-5-desaturase
Eicosapentaenoic Acid (20:5ω-3)
↓ Elongase
Docosapentaenoic Acid (22:5ω-3)
↓ Elongase
Tetracosapentaenoic Acid (24:5ω-3)
↓ Δ-6-desaturase
Tetracosahexaenoic Acid (24:6ω-3)
↓ β-oxidation
Docosahexaenoic Acid (22:6ω-3)

Pathways from Fatty Acids:
From Arachidonic Acid (20:4ω-6):
- COX leads to PGE₂-series, PC₂-series, TX₂-series
- Lipoxygenase leads to LT₄-series, Lipoxins

From Eicosapentaenoic Acid (20:5ω-3):
- COX leads to Resolvins E-series, PGE₃-series, TX₃-series
- Lipoxygenase leads to LT₅-series

From Docosahexaenoic Acid (22:6ω-3):
- Oxygenases lead to Resolvins D-series, Protectins, Maresins::>
↓ LA leads to, by default, elongation of OO(18:1ω-9), resulting in
↑Mead Acid (20:3ω-9) and a
↑ T-T ratio [Mead Acid (20:3ω-9):Arachidonic Acid (20:4ω-6)]

<a id='4d1b8090-1b11-4ece-bc25-7012967f63ee'></a>

NASPGHAN
FOUNDATION

<a id='c7a35ca5-365e-4ad8-8bb9-2a6d91ff2a00'></a>

Chan AP, et al. Clin Perinatol. 2023;50(3):575-89.

<a id='dd855495-57c6-48e0-bd94-fe97b7565626'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, italicized text "NASPGHAN" on a light blue gradient background, underlined by a dark blue curved swoosh.::>

<a id='0356acb7-2581-4073-adff-e1b58e904339'></a>

↑1:1 ratio [Mead Acid (20:3ω -9):Arachidonic Acid (20:4ω-6)]

<a id='21d4cfef-1f6c-4f2e-bfc7-2344d407dc4d'></a>

Essential Fatty Acid Deficiency
• Biochemical Indicators (T:T > 0.2)
  • ↑ LFTs
  • ↑ Triglyceride
  • ↓ Platelet
• Physical Signs (T:T > 0.4)
  • Dry, scaly rash
  • Poor wound healing
  • Growth restriction
  • Increased infection risks
  • Bleeding
<::Two side-by-side black and white photographs of a child. The left image shows a child with a severe dry, scaly rash covering their body, indicative of essential fatty acid deficiency. The right image shows the same child after successful treatment, with clear skin and appearing healthier.
Child with essential fatty acid deficiency (left)
after successful treatment (right)
: photo::>

<a id='e0c417f3-cf21-4256-9078-4d61afc07683'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='ec4fb67d-ff0c-40d5-a66d-9726dc88105b'></a>

Uauy R, et al. Semin Pereinatol. 1989;13:118-30.

<a id='ed983feb-4f23-4dac-ac34-fb33a01439bd'></a>

CAPTION ERROR

<a id='9e8892be-88cd-412b-be79-5a3bc56ff00b'></a>

# Essential Fatty Acid Deficiency
* Prevention
  * Provide IV lipids at appropriate dosage
  * Fish oil provides “conditionally essential” fatty acids, arachidonic acid and docosahexaenoic acid (DHA), that can be retro converted to linoleic acid and eicosapentaenoic acid (EPA), respectively

<a id='30346541-b73a-4b63-a454-c766b6fda080'></a>

* Treatment
  * Administer either 100% soybean oil or 100% fish oil IV lipid

<a id='c72568ef-545b-4355-ac78-25949ee7e2ce'></a>

<::table
| | SO-ILE | SO, MCT, OO, FO-ILE | FO-ILE |
| :---------------------- | :------- | :------------------ | :------- |
| Minimum Dosage (g/kg) | 0.5 – 1.0 | 2.2 – 3.0 | 1.0 – 1.5 |
:table::>

<a id='26bcb7a0-fe7f-4a3a-ae3d-5e5bc5a68664'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='53b731bb-f845-4558-b929-c328299dbe74'></a>

Gramlich L, et al. J Parent Enteral Nutr. 2019;43(6):697-707.
Gura K, et al. J Pediatr. 2020;219:98-105.e4.
de Meijer VE, et al. J Pediatr Gastroenterol Nutr. 2010;50:212-18.

<a id='6bc306ba-e7af-4338-a1ea-ab782edfb64f'></a>

CAPTION ERROR

<a id='6fbeaf1b-4a40-408b-9db0-cb1cf03e483d'></a>

# Hypertriglyceridemia

*   Definition
    *   Triglyceride level > 250-300 mg/dL

*   Risk Factors
    *   Prematurity (< 28 weeks' gestation)
    *   Low birth weight (< 1000 g)
    *   IV lipid (based on dose ,concentration, oil source)
    *   Sepsis
    *   Renal failure
    *   Corticosteroids
    *   Dextrose overfeeding
    *   Essential fatty acid deficiency
    *   Inborn errors of metabolism
    *   Carnitine deficiency

<a id='8134f506-29a9-405d-b335-e45f64a2ac1f'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='ab4509cf-0e1c-4d56-b4e9-c6c16013f0cd'></a>

Chan AP, et al. *Neoreviews* 2022;23(8):e528-e540.
Mirtallo J, et al. *J Parenter Enteral Nutr.* 2004;28(6):S39-S70.
Lapillonne A, et al. *Clin Nutr.* 2018;37(6 Pt B):2324-336.

<a id='a67564bf-a345-4874-bfbf-da5e65a8a725'></a>

CAPTION ERROR

<a id='578d98fe-e897-4518-9a06-32b6d34d1408'></a>

Hypertriglyceridemia

<a id='36274748-fb75-4a2f-bd57-62f17033f938'></a>

<table id="21-1">
<tr><td id="21-2">Management of HTG</td><td id="21-3">Comments</td></tr>
<tr><td id="21-4">Ensure lab specimen is not contaminated</td><td id="21-5"></td></tr>
<tr><td id="21-6">Avoid excessive dextrose infusions</td><td id="21-7">May limit nonprotein calories</td></tr>
<tr><td id="21-8">Administer ILE over longer period</td><td id="21-9"></td></tr>
<tr><td id="21-a">Treat sepsis and renal failure</td><td id="21-b"></td></tr>
<tr><td id="21-c">Normalize serum calcium to optimize LPL activity</td><td id="21-d"></td></tr>
<tr><td id="21-e">Minimize use of medications associated with HTG (corticosteroids, chlorothiazide)</td><td id="21-f"></td></tr>
<tr><td id="21-g">Reduce ILE dose or pause ILE</td><td id="21-h">Ensure infant's risk for EFAD is low and ILE dose will not cause an EFAD</td></tr>
<tr><td id="21-i">Change ILE type to include fish oil</td><td id="21-j">w-3 fatty acids in fish oil enhance lipid utilization, accelerate lipid clearance, and suppress lipogenesis</td></tr>
<tr><td id="21-k">Heparin</td><td id="21-l">Induces triglyceride clearance, but increased bleeding risk should be considered</td></tr>
<tr><td id="21-m">Carnitine</td><td id="21-n">Enhances fatty acid oxidation, but evidence on clinical effectiveness is limited</td></tr>
</table>

<a id='76b8e596-4782-4bbf-b3e0-811f346be5f7'></a>

<::NASPGHAN
FOUNDATION
: figure::>

<a id='57030a32-2043-41da-8220-6ad9ee786b9e'></a>

Chan AP, et al. Neoreviews 2022;23(8):e528-e540

<a id='f9d9c1ff-dfcb-4c32-ae2e-d05872b6d0a8'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, bold, italicized text "NASPGHAN" on a light blue gradient background, with a dark blue curved line beneath it.::>

<a id='b4968004-7784-4a2f-a906-31770793b967'></a>

Growth Monitoring Charts

*   Growth curves used to track weight, length, and head circumference for age
*   Selection of growth chart depends on patient age, gender, institutional preference, and specific underlying conditions (Down syndrome, Rett syndrome, etc.)
    *   Olsen: up to 36 weeks gestational age
        *   Intrauterine growth curves based on data from US
    *   Fenton: most used, best between 36-50 weeks corrected age
        *   Combination of intrauterine and postnatal curves based on data from Canada, Australia, Italy, Scotland, Germany, and US
    *   World Health Organization: after 4-8 weeks post-term until 2 years old
        *   International postnatal growth standards based on breastfed children

<a id='a0012130-0126-49c4-ad93-a82fffae6336'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='5446ef3f-fd79-43db-99bb-2a53b742636d'></a>

Olsen IE, et al. Pediatrics 2010;125(2):e214–e224.
Fenton TR, et al. BMC Pediatr. 2013;13:59.
WHO Multicentre Growth Reference Study Group. Acta Paediatr. 2006;450(Suppl):76–85.

<a id='e176218e-af9b-4463-ad97-78157bec69bd'></a>

CAPTION ERROR

<a id='fcb09235-5584-47ca-8279-3205e0339ab5'></a>

# Growth Monitoring Target Goals

* Once birth weight is achieved, the following growth goals should be targeted

<a id='799b2ca9-b31f-4b0e-9874-5110760ffeff'></a>

* Accurate growth monitoring may be difficult if edema is present

<a id='83a30834-fbda-4bd0-9e26-f6d6c032f7c2'></a>

<::table
| | Weight | Length | Head Circumference |
|---|---|---|---|
| Preterm Infant | 15-20 g/kg/day | 1 cm/week | 0.7 cm/week |
| Term Infant (0 – 3 months) | 30 g/day | 0.75 cm/week | 0.5 cm/week |
: table::>

<a id='f7b9ac67-f2f9-4731-8d71-051ed3f0347b'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='e6bf519b-7282-4380-ae0d-5802ed7e28d3'></a>

Water as Nutrition. In: Nutritional Needs of the Preterm Infant: Scientific Basis and Practical
Guidelines. Editor: Tsang. Baltimore 1992.
Fenton TL, et al. J Pediatr. 2018;196:77-83.

<a id='71910ca0-9c53-4273-ace8-76037ba3c62f'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, bold, italicized text "NASPGHAN" on a light blue to white gradient background, with a dark blue curved line beneath it.::>

<a id='e72f5f46-dfae-4b45-a6e4-2ea0b29d208b'></a>

## Neonatal PN: Heparin

*   Prophylactic to prevent thrombosis
*   Reduces the formation of a fibrin sheath around the catheter
*   May reduce phlebitis with peripheral intravenous access
*   May facilitate lipid clearance; increased lipolysis and release of free fatty acids
*   Reduces the incidence of culture-positive catheter-related sepsis
*   Heparin dosing
    *   1 unit/mL full-term infants-adults
    *   0.5 units/mL preterm and VLBW infants (<1500g)
*   Cons: ↑risk for heparin-induced thrombocytopenia and heparin medication interactions

<a id='019e243c-abfb-4706-9189-6b1ce07c1240'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='787e7402-286c-4f0c-b5f7-5f5894d49bcd'></a>

Birch P, et al. Arch Dis Child Fetal Neonatal Ed. 2010;95(4):F252-7.
Uslu S, et al. J Perinatol. 2010;30(12):794-9.
Kerner JA. "Parenteral Nutrition" in Nutrition in Pediatrics 3rd Editon, 2003:969.

<a id='df271ad8-c445-4789-bb99-0a194051030f'></a>

<::logo: NASPGHAN
NASPGHAN
The logo displays the dark blue text "NASPGHAN" on a blue gradient background, accented by a curved dark blue swoosh beneath the text.::>

<a id='059da6c5-346b-4b34-82a8-f492fae4130c'></a>

<::Essential Micronutrients: Organic
: flowchart::>
<::Vitamins
  <::Water Soluable
    <::Non-B-complex
      Ascorbic acid (c)
    ::>
    <::B-complex
      <::Energy releasing
        - Thiamine (B1)
        - Riboflavin (B2)
        - Niacin (B3)
        - Pantothenic acid (B5)
        - Biotin (B7)
      ::>
      <::Hematopoetic
        - Folic acid (B9)
        - Cyancobalamin (B12)
      ::>
      <::Other
        - Pyridoxine (B6)
        - Pyridoxal
        - Pyridoxamine
      ::>
    ::>
  ::>
  <::Fat Soluable
  ::>
::>
*Micronutrients must always be administered
*The major risk factor for deficiency is omission from PN

<a id='57389a2a-f671-4fe6-a01a-5ab404f54b6f'></a>

NASPGHAN
FOUNDATION

<a id='12c3dc2f-0f33-4480-87e6-162dd0f52012'></a>

Birch P, et al. Arch Dis Child Fetal Neonatal Ed. 2010;95(4):F252-7.
Uslu S, et al. J Perinatol. 2010;30(12):794-9.
Randolph AG, et al. Chest 1998;113(1):165-71.
Kerner JA. "Parenteral Nutrition" in Nutrition in Pediatrics 3rd Editon, 2003:969.

<a id='48a3d59f-bd4c-48a6-b9b1-fb933917cb2b'></a>

CAPTION ERROR

<a id='472a7219-5f4d-42df-a7a6-bf1a80cf0db8'></a>

Essential Micronutrients: Inorganic

<a id='4d75f37d-3133-4a08-b49f-e8534b2a7252'></a>

- Micronutrients must always be administered

- The major risk factor for deficiency is omission from PN

<::
| Electrolytes | Minerals |
|:-------------|:---------|
| Sodium       | Iron     |
| Potassium    | Iodide * |
| Mangesium    | Zinc     |
| Phosporus    | Copper   |
| Calcium      | Chromium |
|              | Manganese|
|              | Selenium |
|              | Cobalt   |
|              | Molybdenum|

* PN Iodine not available in the USA
: table::>


<a id='74526743-c366-49b4-a528-ac64f90dfd51'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='ae86e214-46cf-4135-9ba7-04149dc6e48b'></a>

Birch P, et al. Arch Dis Child Fetal Neonatal Ed. 2010;95(4):F252-7.
Uslu S, et al. J Perinatol. 2010;30(12):794-9. Randolph AG, et al. Chest 1998;113(1):165-71.
Kerner JA. "Parenteral Nutrition" in Nutrition in Pediatrics 3rd Editon, 2003:969.

<a id='25914056-d387-45c7-9d82-bab62f6e346a'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features bold, italicized, dark blue text "NASPGHAN" on a light blue rectangular background with a subtle gradient, and a dark blue curved line sweeping underneath the text.::>

<a id='f7113ac1-0516-44c6-abaf-1e88694da43f'></a>

Comparison of Infant and Child Dosing of Electrolyte and Minerals

<a id='bcc6e83d-2c3a-4f6a-8e31-b94bca6665ce'></a>

<table id="27-1">
<tr><td id="27-2"></td><td id="27-3">Infant (0 – 5 kg)</td><td id="27-4">Infant / Child (5 – 20 kg)</td></tr>
<tr><td id="27-5">Sodium</td><td id="27-6">2 – 5 mEq/kg</td><td id="27-7">2 – 6 mEq/kg</td></tr>
<tr><td id="27-8">Potassium</td><td id="27-9">2 – 4 mEq/kg</td><td id="27-a">2 – 3 mEq/kg</td></tr>
<tr><td id="27-b">Chloride</td><td id="27-c">2 – 5 mEq/kg</td><td id="27-d">2 – 5 mEq/kg</td></tr>
<tr><td id="27-e">Acetate</td><td id="27-f">Balance</td><td id="27-g">Balance</td></tr>
<tr><td id="27-h">Calcium</td><td id="27-i">1-4 mEq/kg</td><td id="27-j">0.5-1 mEq/kg</td></tr>
<tr><td id="27-k">Phosphorus</td><td id="27-l">2-4 mEq/kg</td><td id="27-m">1-2 mEq/kg</td></tr>
<tr><td id="27-n">Magnesium</td><td id="27-o">0.3-0.5 mEq/kg</td><td id="27-p">0.3 - 0.5 mEq/kg</td></tr>
</table>
*Assumes normal age-related organ function and normal losses

<a id='2e671e6b-3f7c-4c18-ad5f-ed189d906efe'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='e1743e3c-f413-48f3-9050-045d767670ad'></a>

Klein RE. Pediatric Nutrition Handbook 8th Edition 2020.

<a id='f3ffc4bc-04b3-44fb-9c3f-887b3c6f226d'></a>

CAPTION ERROR

<a id='8faaf67c-4762-4b63-bc21-8c1730ddffca'></a>

# Electrolytes: Acid / Base Balance

* Chloride: provided as Na chloride, K chloride, and as part of cysteine hydrochloride
  * Avoid prolonged use of chloride free-PN without close monitoring as it may increase the risk of metabolic alkalosis
* Bicarbonate can't be added to PN due to compatibility issues
* Acetate: provided as Na or K acetate
  * K acetate has significantly lower aluminum content (200 mcg/L) compared to Na acetate (360 mcg/L)
  * Metabolized to bicarbonate and added to counter metabolic acidosis

<a id='557453aa-2cc3-4a8a-a1a4-2fa9f46a2504'></a>

NASPGHAN
FOUNDATION

<a id='cc37e5d5-fe8f-4ed9-bedb-22668783ca47'></a>

Smith BS, et al. Am J Health Syst Pharm. 2007;64:730–39.
Bohrer D, et al. J Parenter Enteral Nutr. 2002;26:382–89.
Bishop NJ, et al. N Engl J Med. 1997;336:1557–61.

<a id='132ef3a7-c40d-44ad-844c-e34c5461eca8'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, bold, italicized text "NASPGHAN" on a light blue gradient background, with a dark blue curved line sweeping underneath the text.::>

<a id='15f736db-7eb2-44d1-b9af-ee688c0a82ec'></a>

# Calcium and Phosphorus Challenges

*   Due to rapid bone accretion, infants require much higher Ca and Phos content per PN volume and per kg body weight than older children and adults
*   Risk of precipitation is much greater in infants and should be considered with every PN order

<a id='6e324363-e165-4e26-b301-6c38e5a036b5'></a>

- Metabolic bone disease is common in preterm infants and those receiving long-term PN
  - Monitor serum levels closely
  - Adjust Ca and Phos daily in PN if needed
  - Ca and Phos should be dosed in a ratio that optimizes their deposition into bone

<a id='7da7bf76-576c-4ddc-9a6e-84aaf40081ca'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='7eb01abc-a511-4dc6-855d-e868f3c715fa'></a>

Mihatsch W, et al. Clin Nutr. 2018;37:2360-65.
Groh-Wargo S, et al. Clin Perinatol. 2022;49:355-79.
Porcelli PJ, et al. J Am Coll Nutr. 1997;16(3):283-7.

<a id='f7765d3a-14f0-43cd-a2c9-e0f236bb6b3a'></a>

CAPTION ERROR

<a id='485c9c2b-7497-4658-a69b-1430c287a47f'></a>

Calcium and Phosphorus Challenges – Cont'd

*   Ideal Ca:Phos ratio
    = 1.3-1.7:1 by weight ratio (mg: mg)
    = 1.1-1.3:1 molar ratio (mmol:mmol or mEq:mEq)
    = 0.8-1.0** molar ratio during first 5-7 days in
    newborn preterm infants at risk for
    postnatal hypercalcemia and
    hypophosphatemia

<a id='47dae2ff-675e-4a0c-96fc-74023fcdb5c4'></a>

- Ca and Phos in PN are based on both recommended intakes and ratios of these nutrients and the compounding limits of solubility

**In early PN when calcium and phosphorous intakes are low, and protein and energy are optimized it is recommended to use a molar Ca:P ratio below1 (0.8-1.0) to reduce the risk of early postnatal hypercalcemia and hypophosphatemia.

<a id='62220130-c64d-40e3-a5c9-b978db124000'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='2c387502-a01e-4830-9a8a-c07e28c7ad37'></a>

Mihatsch W, et al. Clin Nutr. 2018;37:2360-65.
Groh-Wargo S, et al. Clin Perinatol. 2022;49:355-79.
Porcelli PJ, et al. J Am Coll Nutr. 1997;16(3):283-7.

<a id='4573e42a-f0ed-480b-b702-37ac9d77be28'></a>

<::logo: NASPGHAN\nNASPGHAN\nThe logo features dark blue, bold, italicized text "NASPGHAN" on a blue gradient background, with a curved dark blue line underneath.::>

<a id='eecdad43-ebe1-42e6-a72c-435978f9066c'></a>

# Calcium/Phosphorus Solubility & Cysteine

* Cysteine is considered an essential amino acid for preterm infants
* Can be added to the PN solution
* Lowers pH of the solution allowing increased solubility of Ca and Phos
* Cysteine improves nitrogen balance in extremely low birth weight infants
* Dosing recommendation is 40 mg cysteine/g of pediatric amino acid solution
* Addition of cysteine may necessitate supplementation with acetate in preterm infants and possibly other patients prone to acidosis

<a id='90e55540-b7ec-47ec-8e8a-e919cef083d5'></a>

<::NASPGHAN FOUNDATION logo with a blue gradient background: figure::>

<a id='07365db1-58ae-4f0a-b5df-c4ba11c6c060'></a>

Groh-Wargo S, et al. Clin Perinatol. 2022;49:355-79.
Shulman RJ, et al. J Pediatr Gastroenterol Nutr. 2003;36:587-607.
Plogsted S, et al. Nutr Clin Pract. 2015;30(4):579-80.

<a id='2b25d969-a908-45eb-a74d-c442e11041d2'></a>

CAPTION ERROR

<a id='f171ea84-170c-4cfd-bf5a-c012fad3f943'></a>

# Carnitine

* May aid triglyceride clearance
  * Facilitates transport of fatty acids across the mitochondrial membrane
* Conditionally essential in the preterm infant
* Serum levels decrease when carnitine is not added to PN
* Consider supplementation
  * Extremely low birth weight premature infants
  * Children on long-term PN (> 2 weeks)
  * Hypertriglyceridemia
  * Significant liver disease

<a id='ddf2eea4-98a2-44b1-83aa-a0b515ecca35'></a>

NASPGHAN
FOUNDATION

<a id='7e114b9a-184b-4908-ab26-2e867b54352a'></a>

Vanek VW, et al. Nutrition Clin Pract. 2012;4:440-91.
Crill CM, et al. Nutr Clin Pract. 2007;22:204-13.

<a id='63d8bfae-0cfa-46ce-849c-f5cf07545e45'></a>

CAPTION ERROR

<a id='7acd69f5-c866-4608-9c5c-401bdae3973c'></a>

# Carnitine – Cont'd

*   Recommended initial dose is Carnitine 2 – 5 mg/kg/day. This may be increased up to 20 mg/kg/day as clinically needed.

<a id='14654ca8-b1eb-43b2-b214-265d9cfcb76d'></a>

• The treatment dose for deficiency is Carnitine 20 mg/kg/day
• Patients with inborn errors of metabolism require very high doses of
carnitine (i.e., 50-100mg/kg) and ideally should be administered
separate from the PN solution to ensure the full dose is received

<a id='6426db3c-1043-42d2-bcb0-c8b2becc8723'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='b89b898c-7b16-490e-bc36-b6eb8672ed16'></a>

Vanek VW, et al. Nutrition Clin Pract. 2012;4:440-91.
Crill CM, et al. Nutr Clin Pract. 2007;22:204-13.

<a id='f10f472f-45a7-4d1c-87a4-62182368a0ed'></a>

CAPTION ERROR

<a id='2c770090-0bf5-4605-835f-68cce95ea2ea'></a>

<::table
: Multivitamin Products and Their Dosages
: INFLUVITE® 2 vial system (4mL of vial 1, 1 mL of vial 2)
: | Component       | Amount     | Component       | Amount     |
: |:----------------|:-----------|:----------------|:-----------|
: | Vitamin A       | 2300 IU    | Vitamin D       | 400 IU     |
: | Vitamin E       | 7 IU       | Vitamin K       | 200 mcg    |
: | Vitamin C       | 80 mg      | Thiamin         | 1.2 mg     |
: | Riboflavin      | 1.4 mg     | Niacin          | 17 mg      |
: | Dexpanthenol    | 5 mg       | Vitamin B6      | 1 mg       |
: | Vitamin B12     | 1 mcg      | Biotin          | 20 mcg     |
: | Folic acid      | 140 mcg    |                 |            |
: 
: Dosage for Infants:
: Infants ≥3 kg: 100% of Vial 1 (4 mL) & Vial 2 (1 mL)
: Infants 1-3 kg: 65% of Vial 1 (2.6 mL) & Vial 2 (0.65 mL)
: Infants < 1 kg: 30% of Vial 1 (1.2 mL) & Vial 2 (0.3 mL)::>

<a id='dcc0ba43-69e5-47db-b6f2-8f0ce06cba84'></a>

NASPGHAN
FOUNDATION

<a id='938b5806-4ade-4e50-8c6b-ccf8f1526ce4'></a>

http://www.hospira.com/Files/MVI_pediatric_PI.pdf
http://www.infuvite.com.PDF/infuvite_PackageInsert.pdf

<a id='d39057f7-6455-442d-9d69-7521c73773c7'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, bold, italicized text "NASPGHAN" on a blue gradient background, with a dark blue curved swoosh underneath.::>

<a id='b206ff21-9166-4af7-ab3b-522b30bec934'></a>

Suggested Intakes of Parenteral Vitamins in
Infants and Children

<a id='8938ceb4-c3d4-4733-ae0a-2b0401ca5fa5'></a>

<::table
: Vitamin
Term Infants and Children
Dose/day
(identical to currently
available formulations)
Preterm Infants Dose/kg body weight
(maximum not to exceed term infant dose)
Current suggestions
(40% of currently available
formulations)
Best Estimate * for New
Formulations
A (mcg)
700
280
500
E (mg)
7
2.8
2.8
K (mcg)
200
80
80
D (IU)
400
160
160
Ascorbic acid (mg)
80
32
25
Thiamin (mg)
1.2
0.48
0.35
Riboflavin (mg)
1.4
0.56
0.15
::>

<a id='ca656fc1-3bea-432b-8582-a133aa2016af'></a>

*Because of elevated levels of water-soluble vitamins, the current proposal is to reduce the intake of water-soluble vitamins and increase retinal.

<a id='894bafb2-b5c3-4b6a-a54f-af7b45175cc1'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='0e763b84-981f-4d95-87f4-fbd8d725138e'></a>

Greene HL, et al. Am J Clin Nutr. 1988;48:1324-42.

<a id='170c5aa1-faa3-4870-afb6-ff7402f7bef5'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the text "NASPGHAN" in dark blue, italicized, sans-serif font, set against a blue gradient background. A dark blue curved line sweeps underneath the text.::>

<a id='296a5cd1-670a-47fe-9cee-d0fcebeb69e4'></a>

Suggested Intakes of Parenteral Vitamins in Infants and Children – Cont'd

<a id='b6890ec3-1c34-4258-80f3-68840b802a15'></a>

<::table:
| Vitamin | Term Infants and Children Dose/day (identical to currently available formulations) | Preterm Infants Dose/kg body weight (maximum not to exceed term infant dose) | Preterm Infants Dose/kg body weight (maximum not to exceed term infant dose) |
|---|---|---|---|
| | | Current suggestions (40% of currently available formulations) | Best Estimate * for New Formulations |
| Pyridoxine (mg) | 1 | 0.4 | 0.18 |
| Niacin (mg) | 17 | 6.8 | 6.8 |
| Pantothenate (mg) | 5 | 2 | 2 |
| Biotin (mcg) | 20 | 8 | 6 |
| Folate (mcg) | 140 | 56 | 56 |
| Vitamin B12 (mcg) | 1 | 0.4 | 0.3 |

*Because of elevated levels of water-soluble vitamins, the current proposal is to reduce the intake of water-soluble vitamins and increase retinal.
::>

<a id='8cab9233-ffc8-40a0-a58a-1393bd09e859'></a>

NASPGHAN
FOUNDATION

<a id='b085a147-b399-4a21-b2c7-14af0c1a23ef'></a>

Greene HL, et al. Am J Clin Nutr. 1988;48:1324-42.

<a id='4d07982b-0945-4077-823e-739049f9627c'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, bold, italicized text "NASPGHAN" on a light blue gradient background, with a dark blue curved line sweeping beneath it.::>

<a id='f23c6655-d79e-4408-9f7e-573aa5d12ee4'></a>

Multivitamins (MVI)

* Must always be administered
* Omission from PN is associated with an increased risk for onset of severe metabolic derangements
* Intolerance of MVIs may occur due to an anaphylactoid reaction to polysorbate – the solubilizing vehicle

<a id='fca49715-177d-4864-8494-afac3e9b60b1'></a>

<::figure
: image:: Two close-up images of a child's face showing a rash. The left image shows a frontal view of the mouth and chin area with red, patchy rash around the lips and on the chin. The right image shows a side view of the cheek and jawline with similar red, patchy rash.
: caption:: Nonimmunologic anaphylactoid rash due to polysorbate—a solubilizing vehicle for MVIs*
::>

<a id='1838373b-0ad4-4bad-a7b5-c1eaff984969'></a>

<::NASPGHAN FOUNDATION logo with "NASPGHAN" in dark blue, bold, italicized text and "FOUNDATION" in red, bold text below it, all on a blue gradient background.::>

<a id='050a5486-0c75-4836-822c-5f73fef45f38'></a>

Greene HL, *et al*. *Am J Clin Nutr*. 1988;48(5):1324-42. CDC. *MMWR Weekly* 1997;46(23);523-28.
Darlington WS, *et al*. *Pediatric Blood Cancer* 2015;62:2232.
Coors EA, *et al*. *Ann Allergy Asthma Immunol*. 2005;95:693-99.

<a id='587da312-1e6b-4e60-9c86-337e494fdca9'></a>

CAPTION ERROR

<a id='8241fa8b-92dc-40b5-ac96-7b4d4f1e32c2'></a>

# MVI Shortage Considerations
* Risk factor for deficiency
  * Omission from PN
    * National shortages
    * History of anaphylactoid reaction to polysorbate 80 (vehicle for MVI)
* Vitamin A is susceptible to photodegradation and oxidization

<a id='e00028c5-2a75-4385-bcd0-8e779fe43477'></a>

- If no pediatric MVI is available, use adult products at reduced doses
  - Infants <2.5 kg or <36 gestation age, can receive an Adult MVI dose of 1 mL/kg up to 2.5 mL/day
  - Vitamin K: daily dose is 200 mcg/day
  - Thiamine: 0.35 to 0.5 mg/kg/day, max 1.2 mg/day

<a id='985c9abf-df7a-4ea8-bc7f-edb83e0c6365'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='c6d2fcc5-d8c5-489d-977d-2b4dbebba661'></a>

Greene HL, et al. Am J Clin Nutr. 1988;48(5):1324-42. CDC. MMWR Weekly 1997;46(23);523-28.
Darlington WS, et al. Pediatric Blood Cancer 2015;62:2232.
Coors EA, et al. Ann Allergy Asthma Immunol. 2005;95:693-99.

<a id='24390d87-5be5-4797-9305-10af62e76e23'></a>

CAPTION ERROR

<a id='ed0752e0-564c-4dff-9831-9c821c758952'></a>

# Neonatal PN: Photodegradation and Oxidation

* Light exposure generates peroxide/free radical formation in PN solutions
  * Both dextrose and AA solutions containing vitamins and intravenous lipid emulsions are prone to peroxidation
  * Premature infants are most susceptible to consequences of peroxide formation in PN admixtures because of immature defense mechanisms and conditions associated with oxidative stress e.g., bronchopulmonary dysplasia, necrotizing enterocolitis, and retinopathy of prematurity
  * Covering PN bags and IV tubing with light protective covers or use of tinted bags and tubing reduces peroxide formation

<a id='056694b9-f735-493d-b9ec-53dc5032b02b'></a>

<::NASPGHAN FOUNDATION logo with a blue gradient background.
: figure::>

<a id='4c6470ce-5c77-4958-ad2d-b9cf81dedfde'></a>

Robinson DT, et al. Nutr Clin Pract. 2021;36:927-41.

<a id='7a9b2134-257f-4e19-aaa9-d6d7d35fa28d'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, bold, italicized text "NASPGHAN" on a blue gradient background, with a dark blue curved swoosh underneath.::>

<a id='7625fbf3-0fc0-4473-9137-08a10ef80908'></a>

# Thiamine Deficiency

*   Thiamine is a coenzyme in biochemical reactions for energy formation, including carbohydrate metabolism, decarboxylation of α-keto acids, pyruvate, and branched-chain amino acids, and transketolase reactions of the pentose phosphate pathway
*   Source: 5 mL Pediatric MVI contains thiamine 1.2 mg
*   Risk: omission of PN multivitamins for ≥ 10+ days
*   Thiamine can be given separately when MVIs are not available
*   Treatment: IV thiamine 25-50 mg

<a id='ea905782-d2c5-4243-8e4f-a6b3fccce318'></a>

SYMPTOMS/SIGNS
* Severe lactic acidosis
* Increased anion gap
* Metabolic acidosis refractory to sodium bicarbonate
* Tachycardia
* Hypotension
* Lethargy
* Beriberi

<a id='5cdaab54-01f9-48bc-9c26-a191c9e3b8af'></a>

NASPGHAN
FOUNDATION

<a id='c8df75b5-a9bc-41dd-b954-ac0bba91d985'></a>

Robinson DT, et al. Nutr Clin Pract. 2021;36:927-41.

<a id='03e882f0-7cd0-4bee-9f2e-b5b83637f66f'></a>

CAPTION ERROR

<a id='8ad5fe3c-7354-4252-8d57-2a813d731db9'></a>

Biotin Deficiency

* Cofactor for four distinct carboxylases that catalyze essential functions in human intermediary metabolism
* Source: 5 mL Pediatric MVI contains Biotin 20 g
* Risk: omission of PN multivitamins
* Symptoms: alopecia totalis, hypotonia, scaly skin rash, and characteristic well-demarcated periorificial dermatitis
* Diagnosis: ↓urinary biotin, ↑urinary organic acids: carboxylase, & propionyl-coenzyme A carboxylase (i.e., biotin-dependent enzymes)

<a id='20456a87-4b1d-4206-a61a-b408e08071f3'></a>

<::A split image showing two black and white photographs of a baby. The left image is a close-up of the baby's face, showing a rash around the eyes and mouth. The right image is a close-up of the baby's lower torso, showing the genital and perianal area with a rash. The caption below the images reads: "Well demarcated" periorificial and perianal rash.: figure::>

<a id='f7c6df34-bae4-4881-b985-3f81a450b277'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='5e3f4456-29f1-481d-ae2b-01cad48dc1d3'></a>

Robinson DT, et al. Nutr Clin Pract. 2021;36:927-41.
Mock MM, et al. J Pediatrics 1985;106(5):762-69.

<a id='1004b65a-6ec3-4fb1-97d4-c8ff0ebc512c'></a>

<::logo: NASPGHAN
NASPGHAN
The logo displays the dark blue, italicized text "NASPGHAN" on a light blue to purple gradient background, with a dark blue curved line beneath the text.::>

<a id='bf68aa67-2fc2-43b2-8e68-61a3b2b31b58'></a>

methylcrotonyl-coenzyme A
indicative of a deficiency of

<a id='383204bc-974f-40e0-8c90-585750842855'></a>

Recommended Dosing of Trace Minerals

<a id='f64ca3d7-a5d4-4431-828e-cac6bdc65862'></a>

<table id="42-1">
<tr><td id="42-2">Trace Element</td><td id="42-3">Preterm Neonates</td><td id="42-4">Term Neonates 3 – 10 kg</td><td id="42-5">Children 10 – 40 kg</td><td id="42-6">Adolescents > 40 kg</td></tr>
<tr><td id="42-7">Zinc</td><td id="42-8">400 mcg/kg</td><td id="42-9">250 mcg/kg</td><td id="42-a">50 mcg/kg (max 5000 mcg/d)</td><td id="42-b">2 – 5 mg</td></tr>
<tr><td id="42-c">Copper</td><td id="42-d">20 mcg/kg</td><td id="42-e">20 mcg/kg</td><td id="42-f">20 mcg/kg (max 500 mcg/d)</td><td id="42-g">200 – 500 mcg</td></tr>
<tr><td id="42-h">Manganese</td><td id="42-i">1 mcg/kg</td><td id="42-j">1 mcg/kg</td><td id="42-k">1 mcg/kg (max 5000 mcg/d)</td><td id="42-l">40 – 100 mcg</td></tr>
<tr><td id="42-m">Chromium</td><td id="42-n">0.05 – 0.3 mcg/kg</td><td id="42-o">0.2 mcg/kg</td><td id="42-p">0.2 mcg/kg (max 5 mcg/d)</td><td id="42-q">5 – 15 mcg</td></tr>
<tr><td id="42-r">Selenium</td><td id="42-s">2 mcg/kg</td><td id="42-t">2 mcg/kg</td><td id="42-u">2 mcg/kg (max 100 mcg/d)</td><td id="42-v">40-60 mcg</td></tr>
</table>
*Note: These requirements are different than the multi-trace element products currently available in the USA.

<a id='41aba421-b3c9-4765-8f0a-c2b63862264e'></a>

NASPGHAN
FOUNDATION

<a id='cd7bf746-03b0-470e-92c3-a83abc57e9b4'></a>

CAPTION ERROR

<a id='3c4614b4-cef0-40d5-9f3c-93c4506e3279'></a>

CAPTION ERROR

<a id='8e64ed32-8b64-4709-94e8-673589940dc4'></a>

## Iron (Fe)

*   Parenteral formulation: Fe Dextran
*   Controversial; not recommended as a routine additive
*   Iron dextran requires a test dose and carries an FDA black box warning
*   Not a component of current multiple trace element preparations (limited stability in PN)
*   Risks: potential for increased sepsis; oxidant; risk for anaphylaxis
*   Avoid: in infants < 2 months age; chronic blood transfusions; Fe-overload conditions
*   Dose: 0.1 - 0.2 mg/kg/day for infants > 2 months of age or those with Fe deficiency

<a id='1809a2de-d434-4bfb-83a2-4449c2b0ca4c'></a>

NASPGHAN
FOUNDATION

<a id='f8cf2117-b4ba-4054-9415-4844065d2400'></a>

Greene HL, et al. Am J Clin Nutr. 1988;48(5):1324-42.

<a id='4f5cb958-d147-4cf8-a915-30c1be40c218'></a>

<::logo: NASPGHAN\nNASPGHAN\nThe logo features dark blue, bold, italicized text "NASPGHAN" on a blue gradient background, with a curved dark blue line underneath.::>

<a id='13118a8f-26c6-4d63-be4f-e2824c27ec2c'></a>

## Copper Deficiency

*   Required for co-factor in cuproenzymes
*   Source: present in Multrys® or individually dosed
*   Risk: omission from PN
*   Deficiency effects: anemia, neutropenia, and metabolic bone disease

<::Irregular metaphysis & osteopenia
: figure::>

<::Vacuolated marrow precursors
: figure::>

*   Diagnosis: ↓serum/plasma Copper & Ceruloplasmin
*   Prevention: always include copper and monitor q1-3 months

<a id='bb959af7-fbf1-4255-991a-62de3ce6f007'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='0ea06943-7b5f-4aa8-8b8d-43dd96b39b55'></a>

Marquardt ML, et al Pediatrics 2012;130(3);e695-8.
Angotti LB, et al. Pediatr Blood Cancer 2008;51(5);693-5.
Norton SA, et al. MMWR. 2013;62(7):134-7.

<a id='bb90f87b-c1cd-4f15-867c-57680416caf9'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, italicized text "NASPGHAN" on a blue gradient background, underlined by a dark blue curved swoosh.::>

<a id='3387e802-b610-4bb3-882f-5f2f85fa6bab'></a>

## Zinc Deficiency

*   Required co-factor for enzymes involved maintenance of structural integrity of proteins, regulation of gene expression
*   Source: multitrace and/or individually dosed
*   Risk: omission from PN
*   Deficiency effects: alopecia, acral skin rash, impaired wound healing, growth retardation, diarrhea, hypogeusia

<::A close-up image of a child's hand with a severe skin rash or lesion, possibly a burn or infection, being held by gloved hands. Below it, another image shows a child's foot with similar severe skin conditions, also being held by gloved hands.
: figure::>

*   Diagnosis: ↓ serum/plasma Zinc
*   Prevention: always include Zinc and monitor every 1-3 months

<a id='e3012a81-490b-42f0-8596-9d66a8dc448f'></a>

<::transcription of the content
: NASPGHAN FOUNDATION logo::>

<a id='66f3fa76-4c51-4cc3-bf4a-160c5bb6a18e'></a>

Ruktanonchai D, et al. MMWR. 2013;62(7):134-7.

<a id='e34d9900-1654-4e4e-b092-5e7c3c7cad2f'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, italicized text "NASPGHAN" on a light blue gradient background with a dark blue curved line underneath.::>

<a id='f2ce36ac-4cd6-4489-bd45-6c4985851545'></a>

# Selenium (Se)

*   Should be provided to all patients at initiation of PN
*   Omit in patients with renal disease
*   Increased requirement with oxidative stress, critical illness, and losses (e.g., fistula output, burns, drains)
*   Se status: monitor plasma Se together with a measure of systemic inflammation (↑ C-reactive protein is associated with ↓ plasma Se)

<a id='cb86e393-69fb-4ac3-bb72-8a11661bb2a8'></a>

NASPGHAN
FOUNDATION

<a id='bae4f40a-7501-4c2f-accf-64a393a15119'></a>

Shenkin A. Gastroenterology 2009;137(5 Suppl):S61-9.

<a id='8ab39d59-53dd-4ab9-8360-98810b2a9c11'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, bold, italicized text "NASPGHAN" on a blue gradient background, with a dark blue curved swoosh underneath.::>

<a id='878262ab-df11-4b20-8c8b-f7ed3dd970e6'></a>

# Chromium (Cr)

* Recent data suggests the need to lower the recommended amount of Cr in PN
* Cr improves glucose tolerance in VLWB and ELBW at risk for perinatal hyperglycemia
* Current PN components are contaminated with Cr
* Omit Cr in patients with renal disease or on long-term therapy with PN

<a id='ce643618-5fd8-4ecc-b5cf-ea0e3187918e'></a>

NASPGHAN
FOUNDATION

<a id='a29ef7b1-daf8-4080-a7a7-6a8410126bab'></a>

Capone K, et al. Nutr Clin Pract. 2018;33(3):426-32.
Moukarzel A. Gastroenterology 2009;137(5 Suppl):S18-28.

<a id='76d3ee2a-4ba1-4f89-8216-a94e399fbe92'></a>

CAPTION ERROR

<a id='e90d19c0-91d4-46b5-a821-6ef92f195a4f'></a>

Manganese
• Required for mucopolysaccharide metabolism
• Normally regulated through restricted enteric absorption
• Source: Multrys®
• Toxicity: manganese deposition in basal
ganglia => dopamine depletion
=> Parkinsonian symptoms
• Diagnosis: ↑plasma concentrations
• Prevention: discontinue Multrys®
in chronic PN and give trace minerals
individually
<::Mn deposition in subthalamic nuclei
Two brain MRI scans are shown side-by-side. The left scan is labeled "Control" and shows a normal brain. The right scan is labeled "Mn deposition" and shows hyperintensities in the subthalamic nuclei, indicating manganese deposition.
: image::>

<a id='6a3cd39f-7575-42db-abff-cd4f22b81df4'></a>

NASPGHAN FOUNDATION

<a id='40446ba0-c262-4620-ab09-5e37cf9e0aaa'></a>

Quaghhebeur G, et al. Neuroradiology 1996;38(7):680-83.
Howard L, et al. J Parenter Enteral Nutr. 2007;31(5):388-96.

<a id='1278a01b-a868-40a7-9cb6-d8007bb935c5'></a>

CAPTION ERROR

<a id='9a3cd7dc-a131-423b-8421-c4c2917d1011'></a>

# Chromium

*   Required for glucose regulation, ↑insulin sensitivity
*   Source: Multrys® & natural contaminant in PN solutions
*   Risk: chronic deposition in tissues:
    Kidneys => ↑long-term risk for nephropathy
*   Diagnosis: ↑serum/plasma concentrations
*   Prevention: discontinue multi-trace in
    chronic PN and give other
    trace minerals individually

Chromium accumulation in tissues

<::Box plot titled "CHROMIUM" showing chromium accumulation in HEART, MUSCLE, LIVER, and KIDNEY tissues, measured as Dry Weight in mcg/g. The plot compares "Control" and "HPN" groups.::>

<a id='325424c6-8007-48d8-8522-6d196848b546'></a>

NASPGHAN
FOUNDATION

<a id='d8eb18f8-870c-49aa-9b43-5e4ac4851b4a'></a>

Quaghhebeur G, et al. Neuroradiology 1996;38(7):680-83.
Howard L, et al. J Parenter Enteral Nutr. 2007;31(5):388-96.

<a id='351dd68c-53f4-4159-a2aa-d43fd94a49b0'></a>

CAPTION ERROR